3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body 18F-Fluorodeoxyglucose and 89Zr-Rituximab PET Scans

Acquisition time and injected activity of F-18-fluorodeoxyglucose (F-18-FDG) PET should ideally be reduced. However, this decreases the signal-to-noise ratio (SNR), which impairs the diagnostic value of these PET scans. In addition, Zr-89-antibody PET is known to have a low SNR. To improve the diagnostic value of these scans, a Convolutional Neural Network (CNN) denoising method is proposed. The aim of this study was therefore to develop CNNs to increase SNR for low-count F-18-FDG and Zr-89-antibody PET. Super-low-count, low-count and full-count F-18-FDG PET scans from 60 primary lung cancer patients and full-count Zr-89-rituximab PET scans from five patients with non-Hodgkin lymphoma were acquired. CNNs were built to capture the features and to denoise the PET scans. Additionally, Gaussian smoothing (GS) and Bilateral filtering (BF) were evaluated. The performance of the denoising approaches was assessed based on the tumour recovery coefficient (TRC), coefficient of variance (COV; level of noise), and a qualitative assessment by two nuclear medicine physicians. The CNNs had a higher TRC and comparable or lower COV to GS and BF and was also the preferred method of the two observers for both F-18-FDG and Zr-89-rituximab PET. The CNNs improved the SNR of low-count F-18-FDG and Zr-89-rituximab PET, with almost similar or better clinical performance than the full-count PET, respectively. Additionally, the CNNs showed better performance than GS and BF.

Automated summary

This study aimed to develop Convolutional Neural Networks (CNNs) to increase the signal-to-noise ratio (SNR) for low-count F-18-FDG and Zr-89-antibody PET scans. The CNNs showed higher tumor recovery coefficient (TRC) and comparable or lower coefficient of variance (COV) compared to Gaussian smoothing (GS) and Bilateral filtering (BF), and were preferred by two nuclear medicine physicians. The CNNs improved the SNR of low-count F-18-FDG and Zr-89-rituximab PET with similar or better clinical performance than full-count PET.